🇺🇸 Sofosbuvir-Ribavirin in United States

6 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 6

Most-reported reactions

1. Atrial Fibrillation — 1 report (16.67%)
2. Cerebral Infarction — 1 report (16.67%)
3. Gastric Ulcer Haemorrhage — 1 report (16.67%)
4. Hepatic Failure — 1 report (16.67%)
5. Hepatitis C Rna Increased — 1 report (16.67%)
6. Hepatitis Cholestatic — 1 report (16.67%)

Source database →

Frequently asked questions

Is Sofosbuvir-Ribavirin approved in United States?

Sofosbuvir-Ribavirin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Sofosbuvir-Ribavirin in United States?

Ain Shams University is the originator. The local marketing authorisation holder may differ — check the official source linked above.